Suppr超能文献

非小细胞肺癌患者中γδ T细胞的特征分析

Characterization of γδ T cells in patients with non-small cell lung cancer.

作者信息

Bao Yi, Guo Li, Mo Juanfen

机构信息

Key Laboratory, The Second Affiliated Hospital of Jiaxing College, Jiaxing, Zhejiang 314000, P.R. China.

Department of Oncology, The Second Affiliated Hospital of Jiaxing College, Jiaxing, Zhejiang 314000, P.R. China.

出版信息

Oncol Lett. 2017 Jul;14(1):1133-1140. doi: 10.3892/ol.2017.6191. Epub 2017 May 17.

Abstract

Systemic immune defects that are associated with disease progression exist in a variety of malignancies. γδ T cells are innate-like lymphocytes that do not require self-major histocompatibility complex-restricted priming. -expanded circulating γδ T cells exhibit promising antitumor activity and are a potential candidate for the treatment of various malignancies, including non-small cell lung cancer (NSCLC). In the present study, flow cytometry was used as a method to study the phenotypes and characteristics of γδ T cells. A lower frequency of circulating γδ T cells was observed in NSCLC patients than in healthy controls. In advanced NSCLC patients, γδ T cells were also detected in the pleural effusion, but the frequency of γδ T cells here was significantly lower than in the peripheral blood. Vδ1and Vδ1Vδ2 T cells represented the most enriched subsets in the pleural effusion. Moreover, the present study demonstrated that Vδ1 T cells are a type of γδ T cells characterized by a cluster of differentiation (CD)3 T-cell receptor (TCR)γδ phenotype, whereas Vδ2 T cells represent a CD3TCRγδ phenotype, according to the fluorescence intensity of CD3 and γδTCR using flow cytometry. Finally, the present study reported a decrease in the expression of CD27 and CD28 molecules on the surface of circulating γδ T cells in NSCLC. The present data suggest the existence of a dysregulated repertoire of γδ T cells in NSCLC, which exhibit impaired activation and a reformed cytokine-releasing profile. Although the expansion of γδ T cells may be a prospective therapeutic strategy in NSCLC patients, it remains necessary to clarify which subsets (Vδ1 or Vδ2) should be expanded and the sources from which γδ T cells should be generated.

摘要

与疾病进展相关的全身性免疫缺陷存在于多种恶性肿瘤中。γδ T细胞是一类天然淋巴细胞,不需要自身主要组织相容性复合体限制的启动过程。扩增的循环γδ T细胞表现出有前景的抗肿瘤活性,是治疗包括非小细胞肺癌(NSCLC)在内的各种恶性肿瘤的潜在候选者。在本研究中,流式细胞术被用作研究γδ T细胞表型和特征的方法。NSCLC患者中循环γδ T细胞的频率低于健康对照。在晚期NSCLC患者的胸腔积液中也检测到了γδ T细胞,但此处γδ T细胞的频率显著低于外周血。Vδ1和Vδ1Vδ2 T细胞是胸腔积液中最丰富的亚群。此外,本研究表明,根据流式细胞术检测的CD3和γδTCR的荧光强度,Vδ1 T细胞是一种具有分化簇(CD)3 T细胞受体(TCR)γδ表型的γδ T细胞,而Vδ2 T细胞代表CD3TCRγδ表型。最后,本研究报道NSCLC患者循环γδ T细胞表面CD27和CD28分子的表达降低。目前的数据表明NSCLC中存在γδ T细胞库失调,其表现为激活受损和细胞因子释放谱改变。虽然γδ T细胞的扩增可能是NSCLC患者的一种前瞻性治疗策略,但仍有必要明确应扩增哪些亚群(Vδ1或Vδ2)以及γδ T细胞的来源。

相似文献

引用本文的文献

2
T lymphocyte cell: A pivotal player in lung cancer.T 淋巴细胞:肺癌的关键参与者。
Front Immunol. 2023 Jan 27;14:1102778. doi: 10.3389/fimmu.2023.1102778. eCollection 2023.
3
Comparing Mouse and Human Tissue-Resident γδ T Cells.比较鼠类和人类组织驻留 γδ T 细胞。
Front Immunol. 2022 Jun 8;13:891687. doi: 10.3389/fimmu.2022.891687. eCollection 2022.

本文引用的文献

5
γδ T cell therapy for the treatment of non-small cell lung cancer.γδ T 细胞疗法治疗非小细胞肺癌。
Transl Lung Cancer Res. 2014 Feb;3(1):23-33. doi: 10.3978/j.issn.2218-6751.2013.11.01.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验